IP Library Granted Patent US 12,383,191
Granted Patent B1
US 12,383,191 · App. 17/306,155 · Granted Aug 12, 2025

Systems and methods for assessing liver pathology

Inventors: Amaro N. Taylor-Weiner (Brooklyn, NY); Harsha Vardhan Pokkalla (Sudbury, MA); Hunter L. Elliott (Boston, MA); Benjamin P. Glass (Boston, MA); Ilan N. Wapinski (Brookline, MA); Aditya Khosla (Lexington, MA); Murray Resnick (Sharon, MA); Michael C. Montalto (Brielle, NJ); Andrew H. Beck (Brookline, MA); Zahil Shanis (Claymont, DE); Aryan Pedawi (Austin, TX); Quang Huy Le (Malden, MA); Jason K. Wang (Los Angeles, CA); Maryam Pouryahya (Bethesda, MD); Kenneth Knute Leidal (Cambridge, MA); Oscar M. Carrasco-Zevallos (Somerville, MA); Dinkar Juyal (Boston, MA); Charles Biddle-Snead (New York, NY); Katy Wack (Pittsburgh, PA)
Assignee: PathAI, Inc.
A61B5/4244A61B5/7267G06T7/0012G16H50/30G16H70/60G06T2207/20081G06T2207/20084G06T2207/30056
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,383,191
App. No.
17/306,155
Filed
May 3, 2021
Granted
Aug 12, 2025
Kind
B1
Art Unit
2681
USPC
382/128
Abstract

In some aspects, the described systems and methods provide for a method for training a deep learning model to assess liver pathology, including accessing annotated liver pathology images associated with a group of patients in one or more randomized controlled clinical trials of nonalcoholic steatohepatitis therapy, each of the annotated liver pathology images including at least one annotation describing one or more tissue characteristic categories for a portion of the image, and training the deep learning model based on the annotated liver pathology images to predict the tissue characteristic categories, selected from a group comprising steatosis, lobular inflammation, hepatocyte ballooning, and fibrosis stage.

Claims (25)

1. A system for training a deep learning model to assess liver pathology, the system comprising:

at least one computer hardware processor; and

at least one non-transitory computer-readable storage medium storing processor-executable instructions that, when executed by the at least one computer hardware processor, cause the at least one computer hardware processor to perform:

accessing a plurality of annotated liver pathology image associated with a group of patients in one or more randomized controlled clinical trials of nonalcoholic steatohepatitis therapy, wherein each of the plurality of annotated liver pathology images includes at least one annotation describing one or more tissue characteristic categories for a portion of the image;

training the deep learning model based on the plurality of annotated liver pathology images to predict the one or more tissue characteristic categories for a liver pathology image, wherein the one or more tissue characteristic categories are selected from a group comprising steatosis, lobular inflammation, hepatocyte ballooning, and fibrosis stage;

storing the trained deep learning model on at least one storage device; and

for a liver pathology image, evaluating a performance of the deep learning model by comparing a fraction of tissue area in the liver pathology image assigned to each NAS component with an ordinal score determined by a pathologist, wherein the ordinal score is determined based on the NAS components, wherein intra-observer reproducibility of the ordinal score of the liver pathology image by multiple pathologists is lower than reproducibility of predictions from multiple iterations of the trained deep learning model processing the liver pathology image,

wherein a group comprising steatosis, lobular inflammation, and hepatocyte ballooning corresponds to components of a nonalcoholic fatty liver disease activity score (NAS).

2. The system of claim 1 , wherein the processor-executable instructions cause the at least one computer hardware processor to further perform:

measuring a feature at or prior to the therapy of a patient, and measuring the feature at a time point following therapy of the patient and calculating differences in feature values to determine treatment-dependent effects.

3. The system of claim 1 , wherein the processor-executable instructions cause the at least one computer hardware processor to further perform:

processing, using the trained deep learning model, a liver pathology image to generate predicted one or more tissue characteristic categories for the liver pathology image; and

generating, for the liver pathology image, based on the predicted one or more tissue characteristic categories, a slide-level continuous score that corresponds to an underlying heterogeneous pattern of fibrosis observed in the liver pathology image.

4. The system of claim 3 , wherein the one or more tissue characteristic categories are predicted on a pixel-level basis.

5. The system of claim 3 , wherein the slide-level continuous score represents a continuum of severity of cellular and stromal injury to capture disease heterogeneity among different patients, wherein an ordinal classification system does not capture the disease heterogeneity among the different patients.

6. The system of claim 1 , wherein the processor-executable instructions cause the at least one computer hardware processor to further perform:

extracting values for a plurality of complex features from each of the annotated liver pathology images, wherein the plurality of complex features includes one or more features not included in the NAS components; and

training the deep learning model based on the plurality of annotated liver pathology images and the values for the plurality of complex features.

7. The system of claim 6 , wherein the plurality of complex features comprises at least one ratio of the NAS components, including a ratio of area of hepatocellular ballooning to steatosis.

8. The system of claim 6 , wherein the one or more features not included in the NAS components include portal inflammation and bile duct.

9. The system of claim 1 , wherein the processor-executable instructions cause the at least one computer hardware processor to further perform:

determining a score for a response metric that captures change in fibrosis pattern before and following the therapy by computing a distance between distribution of fibrosis stages at baseline and following the therapy.

10. The system of claim 9 , wherein the processor-executable instructions cause the at least one computer hardware processor to further perform:

based on a threshold, classifying patients as responder or non-responder to the therapy based on the score for the response metric for a respective patient.

11. The system of claim 1 , wherein the deep learning model comprises one or more deep convolutional neural networks.

Assignments (5)
RELEASE OF SECURITY INTEREST Recorded Jul 28, 2026
From: ORBIMED ROYALTY & CREDIT OPPORTUNITIES IV, LP, AS ADMINISTRATIVE AGENT
To: PATHAI, INC.
Reel/Frame 075427/0613 →
SECURITY INTEREST Recorded Sep 22, 2025
From: PATHAI, INC.
To: ORBIMED ROYALTY & CREDIT OPPORTUNITIES IV, LP, AS ADMINISTRATIVE AGENT FOR SECURED PARTIES
Reel/Frame 072322/0631 →
RELEASE OF SECURITY INTEREST Recorded Sep 18, 2025
From: HERCULES CAPITAL, INC., AS AGENT
To: PATHAI, INC.
Reel/Frame 072300/0731 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 3, 2025
From: TAYLOR-WEINER, AMARO N.; POKKALLA, HARSHA VARDHAN; ELLIOTT, HUNTER L.; GLASS, BENJAMIN P.; WAPINSKI, ILAN N.; KHOSLA, ADITYA; RESNICK, MURRAY; MONTALTO, MICHAEL C.; BECK, ANDREW H.; SHANIS, ZAHIL; PEDAWI, ARYAN; LE, QUANG HUY; WANG, JASON K.; POURYAHYA, MARYAM; LEIDAL, KENNETH KNUTE; CARRASCO-ZEVALLOS, OSCAR M.; JUYAL, DINKAR; BIDDLE-SNEAD, CHARLES; WACK, KATY
To: PATHAI, INC.
Reel/Frame 071608/0138 →
SECURITY INTEREST Recorded Dec 23, 2022
From: PATHAI, INC.
To: HERCULES CAPITAL, INC., AS AGENT
Reel/Frame 062195/0001 →
Continuity (2)
Provisional Application 63157224 · Mar 5, 2021
Provisional Application 63019836 · May 4, 2020
References Cited (31)
US 20180099001A1 · Schentag · 2018 [cited by examiner]
US 20180140219A1 · Yin · 2018 [cited by examiner]
US 20180256526A1 · Hu · 2018 [cited by examiner]
US 20190019300A1 · Simpson · 2019 [cited by examiner]
US 20190021677A1 · Grbic · 2019 [cited by examiner]
US 20200085382A1 · Taerum · 2020 [cited by examiner]
US 20220076410A1 · Georgescu · 2022 [cited by examiner]
US 20220245802A1 · Wang · 2022 [cited by examiner]
[No Author Listed], Gilead Announces Topline Results From Phase 2 ATLAS Study in Patients With Bridging Fibrosis (F3) and Compensated Cirrhosis (F4) Due to Nonalcoholic Steatohepatitis (NASH). Gilead Sciences, Inc. Dec.… [cited by applicant]
[No Author Listed], Noncirrhotic Nonalcoholic Steatohepatitis With Liver Fibrosis: Developing Drugs for Treatment. U.S. Department of Health and Human Services. Food and Drug Administration Center for Drug Evaluation an… [cited by applicant]
Ajmera et al., Refining Sample-Size Estimations Based Upon Placebo Response in Trials of Agents for Nonalcoholic Fatty Liver Disease. Clinical Gastroenterology and Hepatology. 2019; 17(4): 607-609. [cited by applicant]
Brener, Transient Elastography for Assessment of Liver Fibrosis and Steatosis: An Evidence-Based Analysis. Ontario Health Technology Assessment Series. Nov. 2015; 15(18):1-45. [cited by applicant]
Estes et al., Modeling the Epidemic of Nonalcoholic Fatty Liver Disease Demonstrates an Exponential Increase in Burden of Disease. Hepatology. 2018; 67(1): 123-133. [cited by applicant]
Forlano et al. High-Throughput, Machine Learning-Based Quantification of Steatosis, Inflammation, Ballooning, and Fibrosis in Biopsies From Patients With Nonalcoholic Fatty Liver Disease. Clinical Gastroenterology Hepat… [cited by applicant]
Frohmader et al., 1-Wasserstein Distance on the Standard Simplex. AStat Algebraic Statistics. 2021; 12(1):43-56. [cited by applicant]
Goodman, Grading and staging systems for inflammation and fibrosis in chronic liver diseases. Journal of Hepatology. 2007: 47; 598-607. [cited by applicant]
Han et al., Rates of and Factors Associated With Placebo Response in Trials of Pharmacotherapies for Nonalcoholic Steatohepatitis: Systematic Review and Meta-analysis. Clinical Gastroenterology and Hepatology. Mar. 2019… [cited by applicant]
Harrison et al. Selonsertib for Patients with Bridging Fibrosis or Compensated Cirrhosis Due to NASH: Results from Randomized Ph III Stellar Trials. Journal of Hepatology. 2020; 73:26-39. [cited by applicant]
Juluri et al., Generalizability of the Nonalcoholic Steatohepatitis Clinical Research Network Histologic Scoring System for Nonalcoholic Fatty Liver Disease. J. Clin. Gastroenterol. Jan. 2011; 45(1): 55-58. [cited by applicant]
Kleiner et al., Design and Validation of a Histological Scoring System for Nonalcoholic Fatty Liver Disease. Hepatology. Jun. 2005; 41(6):1313-1321. [cited by applicant]
Levina et al., The Earth Mover's Distance is the Mallows Distance: Some Insights from Statistics. Proc. IEEE Int. Conf. Comput. Vis. 2001; 2:251-256. [cited by applicant]
Lichtinghagen et al., The Enhanced Liver Fibrosis (ELF) score: Normal values, influence factors and proposed cut-off values. Journal of Hepatology. 2013; 59: 236-242. [cited by applicant]
Loomba et al., Placebo in Nonalcoholic Steatohepatitis: Insight Into Natural History and Implications for Future Clinical Trials. Clin. Gastroenterol. Hepatol. Nov. 2008; 6(11): 1243-1248. [cited by applicant]
Merriman et al., Correlation of Paired Liver Biopsies in Morbidly Obese Patients With Suspected Nonalcoholic Fatty Liver Disease. Hepatology. 2006; 44(4): 874-880. [cited by applicant]
Olkin et al. The Distance between Two Random Vectors with Given Dispersion Matrices. Linear Algebra and Its Applications. 1982; 48:257-263. [cited by applicant]
Panaretos et al., Statistical Aspects of Wasserstein Distances. Annu. Rev. Stat. Its Appl. 6. 2019; 405-431. [cited by applicant]
Poole et al., Combining dependent P-values with an empirical adaptation of Brown's method. Bioinformatics. 2016; 32: i430-i436. [cited by applicant]
Storey et al., Statistical significance for genomewide studies. Proc. Natl. Acad. Sci. U. S. A. Aug. 5, 2003; 100(16): 9440-9445. [cited by applicant]
Vanderbeck et al., Automatic classification of white regions in liver biopsies by supervised machine learning. Human Pathology. 2014; 45:785-792. [cited by applicant]
Vanderbeck et al., Automatic quantification of lobular inflammation and hepatocyte ballooning in nonalcoholic fatty liver disease liver biopsies. Human Pathology. 2015; 46:767-775. [cited by applicant]
Younossi et al., Nonalcoholic Steatohepatitis Is the Fastest Growing Cause of Hepatocellular Carcinoma in Liver Transplant Candidates. Clinical Gastroenterology and Hepatology. 2019; 17: 748-755.e3. [cited by applicant]